Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Antivenins/*genetics ; Antivenins/*metabolism ; Immunologic Factors/*genetics ; Immunologic Factors/*metabolism ; Recombinant Proteins/*genetics ; Recombinant Proteins/*metabolism ; Snake Bites/*therapy; Africa South of the Sahara ; Antivenins/economics ; Costs and Cost Analysis ; Humans ; Immunologic Factors/economics ; Neglected Diseases ; Recombinant Proteins/economics

Snakebite envenoming is a major public health burden in tropical parts of the developing world. In sub-Saharan Africa, neglect has led to a scarcity of antivenoms threatening the lives and limbs of snakebite victims. Technological advances within antivenom are warranted, but should be evaluated not only on their possible therapeutic impact, but also on their cost-competitiveness. Recombinant antivenoms based on oligoclonal mixtures of human IgG antibodies produced by CHO cell cultivation may be the key to obtaining better snakebite envenoming therapies. Based on industry data, the cost of treatment for a snakebite envenoming with a recombinant antivenom is estimated to be in the range USD 60-250 for the Final Drug Product. One of the effective antivenoms (SAIMR Snake Polyvalent Antivenom from the South African Vaccine Producers) currently on the market has been reported to have a wholesale price of USD 640 per treatment for an average snakebite. Recombinant antivenoms may therefore in the future be a cost-competitive alternative to existing serum-based antivenoms.

Biologicals. 2013 Mar;41(2):93-7. (PMID: 23190453)
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Mar 15;848(1):8-18. (PMID: 16899415)
Am J Trop Med Hyg. 2014 Nov;91(5):887-94. (PMID: 25157124)
Ann Emerg Med. 2011 Feb;57(2):128-137.e3. (PMID: 20952098)
Nat Biotechnol. 2014 Oct;32(10):992-1000. (PMID: 25299917)
PLoS Negl Trop Dis. 2012;6(6):e1670. (PMID: 22679521)
Toxins (Basel). 2016 Jul 23;8(8):null. (PMID: 27455327)
Biotechnol J. 2014 Jun;9(6):766-75. (PMID: 24706569)
MAbs. 2010 Sep-Oct;2(5):480-99. (PMID: 20647768)
PLoS Med. 2006 Jun;3(6):e150. (PMID: 16729843)
MAbs. 2014 Jan-Feb;6(1):197-203. (PMID: 24351421)
Biotechnol Bioeng. 2006 Jun 5;94(2):396-405. (PMID: 16596663)
J Proteomics. 2011 Aug 24;74(9):1735-67. (PMID: 21640209)
J Biotechnol. 2015 Nov 10;213:120-30. (PMID: 26091773)
Curr Opin Biotechnol. 2001 Apr;12(2):188-94. (PMID: 11287236)
Bull World Health Organ. 1998;76(5):515-24. (PMID: 9868843)
Arch Biochem Biophys. 2012 Oct 15;526(2):139-45. (PMID: 22820097)
Toxicon. 2015 Jan;93:79-84. (PMID: 25447775)
Toxicon. 1994 Feb;32(2):185-90. (PMID: 8153957)
Sci Rep. 2016 Nov 08;6:36629. (PMID: 27824133)
Biotechnol Prog. 2007 Sep-Oct;23(5):995-1008. (PMID: 17887772)
J Immunol Methods. 2003 Nov;282(1-2):63-72. (PMID: 14604541)
Nat Rev Immunol. 2010 May;10(5):301-16. (PMID: 20414204)
J Clin Immunol. 2010 Nov;30(6):790-7. (PMID: 20848168)
Biotechnol Bioeng. 2010 Aug 1;106(5):741-50. (PMID: 20564612)
PLoS Negl Trop Dis. 2011 May;5(5):e1144. (PMID: 21610854)
Clin Pharmacokinet. 2003;42(8):721-41. (PMID: 12846594)
Curr Pharm Des. 2016;22(34):5270-5293. (PMID: 27339430)
Nature. 2016 Oct 05;538(7623):41. (PMID: 27708295)
Toxicon. 2015 Sep 15;104:43-5. (PMID: 26238171)
Inflamm Allergy Drug Targets. 2011 Oct;10(5):369-80. (PMID: 21745181)
MAbs. 2009 Sep-Oct;1(5):443-52. (PMID: 20065641)
PLoS Med. 2008 Nov 4;5(11):e218. (PMID: 18986210)
Expert Opin Biol Ther. 2015 Jul;15(7):1015-21. (PMID: 25936923)

0 (Antivenins)
0 (Immunologic Factors)
0 (Recombinant Proteins)

Date Created: 20170204 Date Completed: 20170619 Latest Revision: 20220321

20240829

PMC5310919

10.1371/journal.pntd.0005361

28158193